Literature DB >> 17635518

Mitogen-activated protein kinase signalling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection.

L-J Zhao1, P Zhao, Q-L Chen, H Ren, W Pan, Z-T Qi.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) is a major pathogenic factor of liver diseases. During HCV infection, interaction of the envelope protein E2 of the virion, with target cells, is a crucial process for viral penetration into the cell and its propagation. We speculate that such interaction may trigger early signalling events required for HCV infection.
MATERIALS AND METHODS: Human liver cell line L-02 was treated with HCV E2. The kinase phosphorylation levels of mitogen-activated protein kinase (MAPK) signalling pathways in the treated cells were analyzed by Western blotting. The proliferation of the E2-treated cells was evaluated by MTT assay.
RESULTS: HCV E2 was shown to be an efficient activator for MAPK pathways. Levels of phosphorylation of upstream kinases Raf-1 and MEK1/2 were seen to be elevated following E2 treatment and similarly, phosphorylation levels of downstream kinases MAPK/ERK and p38 MAPK also increased in response to E2 treatment, and specificity of kinase activation by E2 was confirmed. E2-induced MAPK/ERK activation was inhibited by the MEK1/2 inhibitor U0126 in a concentration-dependent manner. Blockage of relevant cellular receptors reduced activation of Raf-1, MEK1/2, MAPK/ERK and p38 MAPK by E2, indicating efflux of the E2 signal from extracellular to the intracellular spaces. Thus, kinase cascades of MAPK pathways were continuously affected by E2 presence. Moreover, enhancement of cell proliferation by E2 appeared to be associated with the dynamic phosphorylation of MAPK/ERK and p38 MAPK.
CONCLUSION: These results suggest that MAPK signalling pathways triggered by E2 may be a potential target for prevention of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635518      PMCID: PMC6496583          DOI: 10.1111/j.1365-2184.2007.00453.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  52 in total

1.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Authors:  D R Taylor; S T Shi; P R Romano; G N Barber; M M Lai
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

2.  Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

Authors:  Hailin Yang; Sung-Kwon Kim; Mikyung Kim; Pedro A Reche; Tiara J Morehead; Inger K Damon; Raymond M Welsh; Ellis L Reinherz
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

3.  Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.

Authors:  Antonio Mazzocca; Silvia Cappadona Sciammetta; Vinicio Carloni; Lorenzo Cosmi; Francesco Annunziato; Takashi Harada; Sergio Abrignani; Massimo Pinzani
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

4.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

Authors:  S Giambartolomei; F Covone; M Levrero; C Balsano
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

6.  Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway.

Authors:  Z Q Yao; D T Nguyen; A I Hiotellis; Y S Hahn
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

7.  Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53.

Authors:  Jeffrey Hildesheim; Dmitry V Bulavin; Miriam R Anver; W Gregory Alvord; M Christine Hollander; Lilit Vardanian; Albert J Fornace
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

8.  CD81 is an entry coreceptor for hepatitis C virus.

Authors:  Emmanuel G Cormier; Fay Tsamis; Francis Kajumo; Robert J Durso; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

9.  Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

Authors:  M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

10.  The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling.

Authors:  Andrew Macdonald; Katherine Crowder; Andrew Street; Christopher McCormick; Kalle Saksela; Mark Harris
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

View more
  11 in total

1.  Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.

Authors:  Wenyu Lin; Wei-Lun Tsai; Run-Xuan Shao; Guoyang Wu; Lee F Peng; Lydia L Barlow; Woo Jin Chung; Leiliang Zhang; Hong Zhao; Jae-Young Jang; Raymond T Chung
Journal:  Gastroenterology       Date:  2010-03-12       Impact factor: 22.682

2.  Proteomic analyses of the effects of drugs of abuse on monocyte-derived mature dendritic cells.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikunar Aalinkeel; B Nair; Donald E Sykes; Stanley A Schwartz
Journal:  Immunol Invest       Date:  2009       Impact factor: 3.657

3.  Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.

Authors:  Mazen Naga; Mona Amin; Dina Algendy; Ahmed Elbadry; May Fawzi; Ayman Foda; Serag Esmat; Dina Sabry; Laila Rashed; Samia Gabal; Manal Kamal
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

4.  Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells.

Authors:  Lan-Juan Zhao; Xian Hua; Sheng-Fei He; Hao Ren; Zhong-Tian Qi
Journal:  Virol J       Date:  2011-04-06       Impact factor: 4.099

5.  Mitogen-Activated Protein Kinase Kinase 2, a Novel E2-Interacting Protein, Promotes the Growth of Classical Swine Fever Virus via Attenuation of the JAK-STAT Signaling Pathway.

Authors:  Jinghan Wang; Shucheng Chen; Yajin Liao; Enyu Zhang; Shuo Feng; Shaoxiong Yu; Lian-Feng Li; Wen-Rui He; Yongfeng Li; Yuzi Luo; Yuan Sun; Mo Zhou; Xiao Wang; Muhammad Munir; Su Li; Hua-Ji Qiu
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

6.  Interaction of L-SIGN with hepatitis C virus envelope protein E2 up-regulates Raf-MEK-ERK pathway.

Authors:  Lan-Juan Zhao; Wen Wang; Hao Ren; Zhong-Tian Qi
Journal:  Cell Biochem Biophys       Date:  2013-07       Impact factor: 2.194

Review 7.  Role of EGF Receptor Regulatory Networks in the Host Response to Viral Infections.

Authors:  Cathleen R Carlin
Journal:  Front Cell Infect Microbiol       Date:  2022-01-10       Impact factor: 5.293

8.  ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN.

Authors:  Lan-Juan Zhao; Wen Wang; Hao Ren; Zhong-Tian Qi
Journal:  Cell Stress Chaperones       Date:  2013-02-03       Impact factor: 3.667

9.  Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection.

Authors:  Miguel Prudêncio; Cristina D Rodrigues; Michael Hannus; Cécilie Martin; Eliana Real; Lígia A Gonçalves; Céline Carret; Robert Dorkin; Ingo Röhl; Kerstin Jahn-Hoffmann; Adrian J F Luty; Robert Sauerwein; Christophe J Echeverri; Maria M Mota
Journal:  PLoS Pathog       Date:  2008-11-07       Impact factor: 6.823

Review 10.  Hepcidin and the iron enigma in HCV infection.

Authors:  Urania Georgopoulou; Alexios Dimitriadis; Pelagia Foka; Eirini Karamichali; Avgi Mamalaki
Journal:  Virulence       Date:  2014-03-13       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.